Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-human CTLA-4×TIGIT bispecific antibody
- Development stage
- Preclinical
- Lead developer
- Logone Bio-Convergence Research Foundation
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
The anti-human CTLA-4×TIGIT bispecific antibody is an investigational immunotherapy designed to selectively target and deplete tumor-infiltrating FOXP3+ regulatory T cells (Tregs). By simultaneously binding to Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) and T cell Immunoreceptor with Ig and ITIM domains (TIGIT), which are highly co-expressed on effector Tregs within the tumor microenvironment, the antibody facilitates targeted Treg depletion via antibody-dependent cellular cytotoxicity (ADCC). This dual-targeting approach aims to overcome the systemic toxicity associated with broad peripheral Treg depletion observed with conventional anti-CTLA-4 monotherapies. Developed through a collaboration involving Logone Bio-Convergence Research Foundation, BitD Inc., and Seoul National University, the antibody has demonstrated potent antigen blocking and enhanced binding affinity in acidic tumor conditions in preclinical models of non-small cell lung cancer (NSCLC).
- Other names
- anti-human CTLA-4×TIGIT BsAbanti-CTLA-4×TIGIT bispecific antibody
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)TIGIT (T cell immunoreceptor with Ig and ITIM domains)
Beyond the preview
Go deeper on anti-human CTLA-4×TIGIT bispecific antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-human CTLA-4×TIGIT bispecific antibody.